Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data for Paxtrava also disclosed, showing substantial reduction in intraocular pressure.
Bluegreen Vacations Holding Corp is expected to report for 4Q. Calavo Growers is expected to report $0.15 for 1Q. Casey s General Stores is expected to report $2.10 for 3Q. Clene Inc. -March 11, 2024 at 06:19 am EDT
- MarketScreener
North American Morning Briefing: Stock Futures -2- morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Intelligent Bio Solutions Inc. showcased their Innovative Drug Screening Technology at the International Mining and Resources Conference in Sydney, Australia this week. The company s innovative.